Products / Onchology y Oncohematology


Cabozantinib 40 - 60 mg

Cabozantinib is indicated for the treatment of patients with advanced Renal Cell Carcinoma (RCC) as first line treatment in combination with nivolumab. Monotherapy in 2nd Line in RCC.

Therapeutic Action



30 coated tablets

This pharmaceutical product is gluten free. Suitable for celiacs.
Cidebin Cabozantinib 40 - 60 mg de Laboratorios Richmond
Download Prospect

Legal Notice

Products which continue to have a valid patent protection at present are manufactured in line with the current laws of the Argentine Republic. Please, take into account that our products will only be shipped to countries where the substance and its use are not protected by patents.

Laboratorios Richmond S.A.C.I.F. Argentina © All rights reserved Terms of use